CONTEXT/ OBJECTIVE: The aim was to characterize rates of change in serum estradiol (E2) levels across the menopausal transition and into early postmenopause. SETTING/PARTICIPANTS: We studied the Michigan Bone Health and Metabolism Study cohort of 629 women with median age of 38 yr (interquartile range, 7) at the 1992-1993 baseline with annual assessment of E2 levels over the subsequent 15-yr period. DESIGN/MAIN OUTCOME MEASURES: The purpose was to describe patterns of acceleration/deceleration in (log)E2 rates of change before and after the final menstrual period (FMP) using nonparametric and piecewise regression modeling. RESULTS: Between -10 to -2 yr to the FMP, mean fitted serum E2 population values were relatively stable. The 95% confidence bands around the slight increase in E2 rate of change 5 yr prior to the FMP included the value of no change. The fitted population mean E2 value declined 67% from 64.5 pg/ml (se = 3.6) to 21 pg/ml (se = 1.2) in the 4 yr between -2 < FMP < +2. A second significant mean E2 rate of change was identified from 6-8 yr after FMP. Fitted population mean E2 values declined 18% from 18.1 pg/ml (se = 1.3) at FMP = 6 to 14.8 pg/ml (se = 1.3) at FMP = 8. In nonobese women, the mean E2 percent decline was 42% from FMP = 6 to FMP = 8, whereas in obese women, the mean E2 percent decline over this time was 31%. CONCLUSIONS: Population mean serum E2 levels were sustained until approximately 2 yr prior to the FMP. In the ensuing 4-yr period, E2 levels declined 67%. A secondary E2 decline, commencing about 6 yr after the FMP, was observed in nonobese but not obese women.
CONTEXT/ OBJECTIVE: The aim was to characterize rates of change in serum estradiol (E2) levels across the menopausal transition and into early postmenopause. SETTING/PARTICIPANTS: We studied the Michigan Bone Health and Metabolism Study cohort of 629 women with median age of 38 yr (interquartile range, 7) at the 1992-1993 baseline with annual assessment of E2 levels over the subsequent 15-yr period. DESIGN/MAIN OUTCOME MEASURES: The purpose was to describe patterns of acceleration/deceleration in (log)E2 rates of change before and after the final menstrual period (FMP) using nonparametric and piecewise regression modeling. RESULTS: Between -10 to -2 yr to the FMP, mean fitted serum E2 population values were relatively stable. The 95% confidence bands around the slight increase in E2 rate of change 5 yr prior to the FMP included the value of no change. The fitted population mean E2 value declined 67% from 64.5 pg/ml (se = 3.6) to 21 pg/ml (se = 1.2) in the 4 yr between -2 < FMP < +2. A second significant mean E2 rate of change was identified from 6-8 yr after FMP. Fitted population mean E2 values declined 18% from 18.1 pg/ml (se = 1.3) at FMP = 6 to 14.8 pg/ml (se = 1.3) at FMP = 8. In nonobese women, the mean E2 percent decline was 42% from FMP = 6 to FMP = 8, whereas in obesewomen, the mean E2 percent decline over this time was 31%. CONCLUSIONS: Population mean serum E2 levels were sustained until approximately 2 yr prior to the FMP. In the ensuing 4-yr period, E2 levels declined 67%. A secondary E2 decline, commencing about 6 yr after the FMP, was observed in nonobese but not obesewomen.
Authors: John F Randolph; MaryFran Sowers; Ellen B Gold; Beth A Mohr; Judith Luborsky; Nanette Santoro; Daniel S McConnell; Joel S Finkelstein; Stanley G Korenman; Karen A Matthews; Barbara Sternfeld; Bill L Lasley Journal: J Clin Endocrinol Metab Date: 2003-04 Impact factor: 5.958
Authors: N A Klein; D E Battaglia; V Y Fujimoto; G S Davis; W J Bremner; M R Soules Journal: J Clin Endocrinol Metab Date: 1996-03 Impact factor: 5.958
Authors: H G Burger; E C Dudley; J L Hopper; N Groome; J R Guthrie; A Green; L Dennerstein Journal: J Clin Endocrinol Metab Date: 1999-11 Impact factor: 5.958
Authors: Mary Fran Sowers; Huiyong Zheng; Howard M Kravitz; Karen Matthews; Joyce T Bromberger; Ellen B Gold; Jane Owens; Flavia Consens; Martica Hall Journal: Sleep Date: 2008-10 Impact factor: 5.849
Authors: John F Randolph; MaryFran Sowers; Irina V Bondarenko; Siobán D Harlow; Judith L Luborsky; Roderick J Little Journal: J Clin Endocrinol Metab Date: 2004-04 Impact factor: 5.958
Authors: MaryFran R Sowers; Huiyong Zheng; Daniel McConnell; Bin Nan; Sioban Harlow; John F Randolph Journal: J Clin Endocrinol Metab Date: 2008-07-22 Impact factor: 5.958
Authors: Siobán D Harlow; Margery Gass; Janet E Hall; Roger Lobo; Pauline Maki; Robert W Rebar; Sherry Sherman; Patrick M Sluss; Tobie J de Villiers Journal: J Clin Endocrinol Metab Date: 2012-02-16 Impact factor: 5.958
Authors: Natalie D Shaw; Serene S Srouji; Stephanie N Histed; Kristin E McCurnin; Janet E Hall Journal: J Clin Endocrinol Metab Date: 2009-06-23 Impact factor: 5.958
Authors: MaryFran R Sowers; Huiyong Zheng; Gail A Greendale; Robert M Neer; Jane A Cauley; Jayne Ellis; Sarah Johnson; Joel S Finkelstein Journal: J Clin Endocrinol Metab Date: 2013-05-10 Impact factor: 5.958
Authors: Mary Fran Sowers; Huiyong Zheng; Howard M Kravitz; Karen Matthews; Joyce T Bromberger; Ellen B Gold; Jane Owens; Flavia Consens; Martica Hall Journal: Sleep Date: 2008-10 Impact factor: 5.849